BioMarin Pharmaceutical Inc. (BMRN)

80,76 -1,37 (-1,67%) Börsenschluss: 04:00PM EDT

BioMarin Pharmaceutical Inc.

770 Lindaro Street
San Rafael, CA 94901
United States
415 506 6700
https://www.biomarin.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 3.401

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Alexander Hardy	President, CEO & Director	1,72M	N/A	1969
Mr. Brian R. Mueller	CFO & Executive VP	1,07M	2,47M	1974
Dr. C. Greg Guyer Ph.D.	Executive VP & Chief Technical Officer	1,11M	N/A	1962
Mr. Jeffrey Robert Ajer	Executive VP & Chief Commercial Officer	1,1M	N/A	1962
Dr. Henry J. Fuchs M.D., Ph.D.	President of Worldwide Research & Development	1,41M	N/A	1958
Ms. Erin Burkhart	Group VP & Chief Accounting Officer	N/A	N/A	1979
Dr. Kevin Eggan Ph.D.	Chief Scientific Officer & Senior VP of Research and Early Development	N/A	N/A	N/A
Traci McCarty	Group Vice President of Investor Relations	N/A	N/A	N/A
Mr. George Eric Davis	Executive VP, Chief Legal Officer, General Counsel & Secretary	1,23M	2,11M	1971
Ms. Humaira Serajuddin	Senior VP & Chief Marketing Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Corporate Governance

BioMarin Pharmaceutical Inc.s ISS Governance QualityScore, Stand 29. April 2024, lautet 4. Die grundlegenden Scores sind Audit: 2, Vorstand: 5, Shareholderrechte: 5, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.